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background:  Overdosing of parenteral antithrombotic drugs can increase the risk of bleeding. Cangrelor is a potent intravenous platelet 
P2Y12 receptor with rapid onset and offset of action. Compared with clopidogrel,cangrelor reduces periprocedural thrombotic complications 
in patients undergoing percutaneous coronary interventions (PCI) without any increase in major bleeding, although minor bleeding is 
increased. The impact of cangrelor overdosing on bleeding is unknown and represented the aim of this analysis.
methods:  Patients with overdosing were identified from the safety population in the CHAMPION program (n=25,107). Overdose was 
defined as administration of >20% of either the bolus dose (30 μg/kg) or infusion rate (4 μg/kg/min). Bleeding complications were 
assessed.
results:  A total of 36 overdosed cangrelor patients were identified (20 with both bolus and infusion, 5 with bolus only, and 11 with infusion 
only). In most cases, the dose did not exceed 2.5 times the recommended dose. Bleeding events were balanced between treatment arms 
and consistent with those in the overall CHAMPION program (Table). Only 1 patient experienced a serious bleed (retroperitoneal bleeding). 
There was no correlation between bleeding and magnitude of cangrelor overdose.
Table. Summary of all bleeding in overdosed patients in CHAMPION studies (safety population).
n (%) of patients
Cangrelor (N=36) Clopidogrel (N=30)
ANY GUSTO BLEEDING 3 (8.3) 4 (13.3)
Severe/life threatening 0 (0.0) 0 (0.0)
Moderate* 1 (2.8) 0 (0.0)
Mild 2 (5.6) 4 (13.3)
Mild excluding ecchymosis, oozing, and <5 cm haematoma 1 (2.8) 2 (6.7)
ANY TIMI BLEEDING 1 (2.8) 1 (3.3)
Major* 1 (2.8) 0 (0.0)
Minor 0 (0.0) 1 (3.3)
Mild excluding ecchymosis, oozing, and <5 cm haematoma 0 (0.0) 1 (3.3)
ANY ACUITY BLEEDING 3 (8.3) 4 (13.3)
Major* 2 (5.6) 1 (3.3)
Major excluding haematoma ≥5 cm 1 (2.8) 0 (0.0)
Minor 1 (2.8) 3 (10.0)
Minor excluding ecchymosis, oozing, and <5 cm haematoma 0 (0.0) 1 (3.3)
ANY BLOOD TRANSFUSION 1 (2.8) 0 (0.0)
*This patient received 1.35 times protocol defined cangrelor dose and experienced retroperitoneal bleeding which was classified as 
GUSTO moderate, ACUITY Major, and TIMI major bleeding.
ACUITY = Acute Catheterization and Urgent Intervention Triage Strategy; GUSTO = Global Use of Strategies to Open Occluded Arteries; 
TIMI = thrombolysis in myocardial infarction.
Conclusion:  In a large clinical trial program of PCI patients, cangrelor overdosing was not associated with an increase in bleeding 
complications, an observation which may be attributed to its very short-half life and rapid offset of action.
